A 8-Week, Multicenter, Open-Label, Observational Study of the Efficacy of Quetiapine Fumarate (SEROQUEL) Immediate-Release Tablets in Adult Patients With Bipolar Depression

AstraZeneca1 个研究点分布在 1 个国家目标入组 2,000 人开始时间: 2007年6月最近更新: 2008年10月6日

适应症

试验速览

To reassure the clinical study data on Seroquel antidepressant efficacy in patients who are diagnosed as bipolar depression

•The patient and the patient's legal representative (if any) must understand the nature of the study and must have given written consent
•Meet DSM-IV-TR criteria for bipolar depression at the time of baseline

•Since this programme intends to describe quetiapine use in routine clinical practice when prescribed as treatment of bipolar depression, there are no programme specific exclusion criteria, other than:
•Or, any of the following is regarded as a criterion for exclusion from the programme:
•Serious or unstable, medical illness. Subjects with chronic illness may be included but must be stable and otherwise physically healthy on the basis of a physical examination, medical history
•Known intolerance for or lack of response to quetiapine, as judged by the investigator

发起方

申办方类型

Industry

Loading locations...